NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









RiboX Therapeutics

RiboX Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://www.riboxtx.com/

Last Round

VC Round

Jul 5, 2022

Company Overview

RiboX Therapeutics is a biotechnology company that focuses on the discovery and development of fully engineered circular RNA therapeutics, a new class of RNA medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

circular RNAcircRNARNA therapyRNA platformlipid nanoparticlesLNP deliveryclinical-stage biotechxerostomia treatmentprotein replacement therapygene medicinerare disease therapydrug discoveryautoimmune disease therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RiboX Therapeutics Comparables

Compare RiboX Therapeutics with similar companies based on industry and business-model similarity.

RiboX Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CirCode Biomedicine
87%
Therorna Inc.
86%
Shanghai CirCode Biomed Co. Ltd.
85%

RiboX Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 5, 2022

RiboX Therapeutics Investors

Notable investors and investment history

RiboX Therapeutics investors
InvestorRounds
TemasekVC Round
Boehringer IngelheimVC Round
Eisai InnovationVC Round
Lilly Asia VenturesVC Round
Qiming Venture PartnersVC Round
Vivo CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 5, 2022

    $110M raised from Boehringer Ingelheim Venture Fund, Eisai Innovation, and Temasek.

RiboX Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RiboX Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RiboX Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingJul 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.